Join APEX trial investigator Dr Russell Hull for a discussion of the latest substudy exploring betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically in patients, originally presented at ESC 2018.
[template part=”video”]
Register your email and provide your feedback
To help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey[template part=”speaker”]
Topic
Admittance of a patient to the intensive care unit (ICU) is a predictor of venous thromboembolism. In this informative journal club, Dr Russell Hull provides insights into the latest APEX trial retrospective analysis looking at extended-duration prophylaxis by betrixaban, and whether this novel regimen yielded clinical benefit with respect to reduced bleeding and VTE risk when compared with the current standard of care by enoxaparin.
[template part=”details”]
